We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

By LabMedica International staff writers
Posted on 21 Sep 2014
The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. More...


A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015. “In an area like cancer, where time is of the essence, the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs,” stated Steven Alberts, MD, chair of medical oncology at Mayo Clinic. The researchers hope the increased speed also will speed new discoveries.

Clinical trials provide patients with access to new and emerging treatments; however, enrolling participants in trials is one of the more problematic areas of clinical research. Currently it is done manually, with clinical coordinators sifting through patient records and conditions, trying to correlate them with the requirements of a given study protocol. At any given time, Mayo Clinic is conducting over 8,000 human studies in addition to the 170,000 that are ongoing worldwide. Watson’s cognitive computing ability will help sift through available Mayo clinical trials and ensure that more patients are effectively and consistently matched with promising clinical trial options.

“With shorter times from initiation to completion of trials, our research teams will have the capacity for deeper, more complete investigations,” said Nicholas LaRusso, MD, a Mayo Clinic gastroenterologist and the project lead for the Mayo-IBM Watson collaboration. “Coupled with increased accuracy, we will be able to develop, refine, and improve new and better techniques in medicine at a higher level.”

This version of Watson will be expressly designed for Mayo Clinic. As it progresses in its tasks and matures through this collaboration, it will learn more about the clinical trials matching process, become even more efficient and likely more generalizable. The Watson computer also may help locate patients for hard-to-fill trials, such as those involving rare diseases.

Many clinical trials at Mayo Clinic and elsewhere are not completed due to lack of sufficient enrollment. Enrollment in general could be increased by the Watson project. In spite of well-organized efforts, even at Mayo Clinic, only 5% of patients take part in studies. In the United States, the rate is even lower, at 3%. Mayo hopes to raise clinical trial involvement to include up to 10% of its patients. Researchers say the higher participation also should improve the quality of research outcomes.

“Using Watson’s cognitive computing capabilities, Mayo Clinic can consistently offer more cutting-edge medical options to patients and conclude trials faster,” said Mike Rhodin, senior vice president, IBM Watson Group. “Ultimately, this effort will also help advance scientific discoveries into promising new forms of care that clinicians can use to treat all patients.”

To make sure that Watson has the required know-how to help with clinical trial matching, Mayo specialists are working with IBM to expand Watson’s body of knowledge to include all clinical trials at Mayo Clinic and in public databases, such as ClinicalTrials dot gov. The new Watson system is being trained to examine patient records and clinical trial criteria to determine appropriate matches for patients.

Mayo and IBM are deliberating on other applications for Watson in the future.

Related Links:

Mayo Clinic
IBM
IBM Watson Cognitive Computer



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.